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Abstract
Background: Widespread parasite resistance to first-line treatment for uncomplicated malaria leads to introduction
of new drug interventions. Introducing such interventions is complex and sensitive because of stakeholder interests
and public resistance. To enhance take up of such interventions, health policy communication strategies need to
deliver accurate and accessible information to empower communities with necessary information and address
problems of cultural acceptance of new interventions.
Objectives: To explore community understanding of policy changes in first-line treatment for uncomplicated
malaria in Kenya; to evaluate the potential role of policy communication in influencing responses to changes in
first-line treatment policy.
Methods: Data collection involved qualitative strategies in a remote district in the Kenyan Coast: in-depth interviews
(n = 29), focus group discussions (n = 14), informal conversations (n = 11) and patient narratives (n = 8). Constant
comparative method was used in the analysis. Being malaria-prone and remotely located, the district offered an ideal
area to investigate whether or not and how policy communication about a matter as critical as change of treatment
policy reaches vulnerable populations.
Results: Three years after initial implementation (2009), there was limited knowledge or understanding regarding
change of first-line treatment from sulphadoxine-pyrimethamine (SP) to artemether-lumefantrine (AL) for treatment of
uncomplicated malaria in the study district. The print and electronic media used to create awareness about the drug
change appeared to have had little impact. Although respondents were aware of the existence of AL, the drug was
known neither by name nor as the official first-line treatment. Depending on individuals or groups, AL was largely
viewed negatively. The weaknesses in communication strategy surrounding the change to AL included poor choice of
communication tools, confusing advertisements of other drugs and conflicts between patients and providers.
Conclusion: Effective health policy communication is important for the uptake of new drug interventions and
adherence to treatment regimens. Besides, prompt access to effective treatment may not be achieved if beneficiaries
are not adequately informed about treatment policy changes. Future changes in treatment policy should ensure that
the communication strategy is designed to pass sustained, accurate and effective messages that account for local
contexts.
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Background
Changes in first-line treatment for uncomplicated malaria
have occurred from chloroquine to antifolate combination
drugs and to the current artemisinin-based combination
therapy (ACT). However, there is no uniformity across
countries in the stages of change from one drug to another
because there are differences in geographical distribution of
resistance to any single antimalarial. Chloroquine (CQ)
was the most widely used anti-malarial drug since it was
first synthesized in 1934 and for many decades was the drug
of choice for treatment of non-severe or uncomplicated
malaria, until drug resistance greatly reduced its use-
fulness [1]. Among the antifolate combination drugs,
sulphadoxine-pyrimethamine (SP), sulphalene-pyrimethamine
(Metakelfin®) and sulphamethoxazole-trimethoprim (co-
trimoxazole) were the most widely used in sub-Saharan
Africa [1]. Antifolate combination drugs did not take long
before widespread global resistance was noted and the
WHO recommended their replacement with ACT for
treatment of both severe and non-severe malaria. The
artemisinin-based combinations have faster parasite clear-
ance and fever resolution than the other drugs [1].
Changing treatment policy is a standard scientific pro-
cedure but such a change needs to be understood by the
entire citizenry who are the targeted beneficiaries. To
reach everyone with adequate and accurate information
about the change in treatment policy, there is a need for
concerted health communication. As noted by [2] poor
health communication is a major contributor to misuse of
health care, non-adherence to treatment regimen and rising
cost of health care. Health communication refers to passing
information about health care that is understood by the tar-
get population [3] so as to allow take-up of an inter-
vention. In disseminating information about the change in
first-line treatment for uncomplicated malaria (i.e. from
SP to artemether-lumefantrine), the target population was
expected to understand and adjust their treatment expec-
tations. Changing and implementing treatment policies
are complex and fraught with challenges at every level.
According to a report by [4] the challenges of changing
and implementing treatment policies range from stake-
holder interests, local and international bureaucracy to
the potential resistance from the intended beneficiaries.
For these challenges, [5,6] recommend accurate and ef-
fective communication of the treatment policy change to
empower the public with information on the value of new
interventions and facilitate uptake and proper utilisation.
There has previously been little detailed study of what pol-
icy communication strategies have accompanied such
drug regimen changes and implementation in most of the
world. Neither has there been a detailed exploration of
people’s perceptions about the changes in first-line treat-
ment policy and how such perceptions influence uptake of
health interventions.
Context and overview of the treatment policy change in
Kenya
Sulphadoxine-pyrimethamine (SP) was introduced in Kenya
in 1998 but by 2001 the treatment failure rate was over
25%, a threshold for changing first-line treatment for
uncomplicated malaria. The Kenya Drug Policy Technical
Working Group met in 2003 and proposed artemether-
lumefantrine (AL) (Coartem®) to replace SP because it was
the only co-formulated ACT recommended by the WHO
as having passed rigorous international regulatory scrutiny.
Artemether-lumefantrine was finally rolled out country-
wide in 2006 after much debate about sustainable finan-
cing and procurement regulations [7].
To implement the change, the MOH conducted train-
ing for health workers at the national, provincial and
district levels. The training recommended parasitic diag-
nosis before administering Coartem® even though the
government of Kenya [8] indicated that only 34% and
7.0% of peripheral facilities countrywide had microscopy
and rapid diagnostic test kits respectively. In addition,
multimedia approaches including road shows, radio, post-
ers and newspapers were used to communicate the policy
change directly to the public in a campaign that lasted
three months [9].
Methods
Study setting
The study was conducted in a remote rural district on the
Kenyan coast. The district was chosen because of the need
to explore how policies get communicated and imple-
mented in remote areas. More specifically, was the need
to understand how policy changes in first-line treatment
of uncomplicated malaria are implemented and how the
same are understood by populations in hard-to-reach lo-
cations. The focus on a hard-to-reach population in an
economically marginalized district was important to the
study as it sought to understand how health interventions
respond to the needs, characteristics and local circum-
stances of populations in remote locations. As stated by
[2] vulnerable populations are most affected by lack of
health information.
Study design and data collection methods
A cross-sectional qualitative study was carried out in
three purposively sampled administrative zones out of
the four that make up the district. Two of the divisions
were farthest from the urban Kinango district headquar-
ters and the other was the location of the headquarters.
This sampling approach was intended to capture any dif-
ferences in experience between people living closest to
the district headquarters and those from the farthest
part of the district. Two villages per division were ran-
domly selected to participate in the study.
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Data were collected between January and February
2009 using document reviews, focus group discussions
(FGDs) (n = 14), in-depth interviews (n = 29), informal
conversations (n = 11) and patient narratives (n = 8). The
number of interviews was not predetermined and inter-
views were stopped on saturation of information. Kiswa-
hili was the main language of communication as it was
the language of the respondents. Participants for FGDs
were selected on the basis of age and gender. They in-
cluded parents with young children aged below ten years
because young children and pregnant women are most vul-
nerable to malaria infection. The range of topics explored
in the FGDs included local information networks and
sources of health information and perceptions about anti-
malarials.
In-depth interviews were conducted with district health
managers, community leaders and managers (in-charges)
of six dispensaries. They provided information on the pol-
icy communication processes and their effectiveness,
implementation challenges and uptake of AL. Table 1
summarizes the range of data collection methods ap-
plied in the study.
Informal conversations were based on chance and dwelt
on communication about health issues and accounting for
Table 1 Summary of data collection methods
Tool Number (n) With whom? Topics explored/Purpose
1. In-depth interviews 29 District health managers (n = 3) 1. Malaria situation in the district
2. Role in policy communication and implementation
3. Uptake of AL in the district
4. Effectiveness of communication strategies
Managers (in-charges) at primary
health facilities (n = 6)
1. Role in policy communication and implementation
2. Perceived effectiveness of policy communication strategies
3. Barriers and facilitators to policy changes/implementation at
the local level
4. Perceived community response to policy changes, attitudes to
recommended drug
Community leaders (n = 17) and
mothers who had recently used
a health facility (n = 3)
1. Experiences with malaria
2. Types of health provision available
3. Views on malaria drugs
4. Views on recent changes in malaria drug
5. Role in the change of drugs
6. Sources of health information and preferred sources
7. Usefulness of the information received
2. Focus Group
Discussions (FGDs)
14 Young parents (male and female) 1. Views on recent malaria drug policy changes
2. Communication about recent drug policy changes;
3. What sort of communication, who got the communication,
from what sources; usefulness of the communication, and
what reactions to the communication.
4. Influences over choice of health care
5. Views over new drugs.
3. Informal
conversations
11 Convenience sample from all age
groups, both male and female
1. Experiences with various malaria drugs
2. Perceptions about policy changes on 1st-line treatment for
uncomplicated malaria
3. Sources of information on government and facility matters
4. Patient narratives 8 Convenience sample of patients
asked to talk about their experiences
Real life experiences when seeking treatment including experience
with various drugs, the reactions to policy change and
communication received about the new policies
5. Document
reviews
6 Selected with the help of the
hospital administrator
To enhance familiarity with content of policy documents and
discussions, and to feedback on policy implementation process
6. Diary 1 Researchers’ experiences/
observations
To enable constant reflection on the researchers’ experiences as
well as helping in identifying emerging thoughts about issues and
ideas that were followed up in subsequent interviews.
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gender differences in the sources of health information as
well as people’s perceptions about changes in malaria
drugs. Patient or caretaker narratives were conducted with
purposively selected patients or caretakers who were will-
ing to talk to the researcher at the health facilities. Those
selected were asked to tell their story about their illness or
illness of the child; how it started, diagnosis, the range of
treatment options undertaken and their effectiveness as
well as their interaction with health workers. All interviews
were audio-recorded except for informal conversations.
Data analysis
All interviews were transcribed and translated into English.
Coding and analysis were performed manually by develop-
ing a matrix for emerging categories and themes. Data
from various sources were first analysed separately and
emerging themes and categories compared later. The
themes and categories centred on phrases, incidents and
behaviour during interviews, discussions, and observa-
tions. In accordance with recommendations of [10,11],
data from each theme or category were identified and ana-
lysed using the constant comparative method. Individual
key informant interviews with health personnel and com-
munity members, for example, were separately compared
and contrasted with each other. Such an approach, ac-
cording to [12,13], helps in identifying patterns, consensus,
differences, variations or contradictions, and in weighing
the relative importance of information based on emphasis
by the study participants. These informed the selection of
data for presentation here.
The criterion for selecting data to present was based
on relevance to the stated objectives. Data presented
here were based on the level of importance as judged by
emphasis and consistency in raising specific issues dur-
ing interviews by study participants.
Ethical approval
Ethical approval was sought from the Kenya Medical
Research Institute (KEMRI) Ethical Review Committee
and the University of Cape Town Ethical Review Board,
Faculty of Health Sciences. All participants gave free and
informed, written and/or verbal consent for the study.
Results
Based on relevance to the objectives, the results were
summarized and presented in relation to three sub-topics
that represented the study participants’ main lines of un-
derstanding of AL and the changes in first-line treatment
policy for uncomplicated malaria. The first part looks at
the study population’s perceptions about general changes
in first-line treatment policy for uncomplicated malaria
over time, because such perceptions have a bearing on
take-up of new drug interventions. The second part ex-
plores perceptions specific to the change from SP to AL
including views of the study participants about the im-
portance of AL as a first-line drug. The last part addresses
barriers to health policy communication that most likely
influenced poor uptake of AL and identifies key variables
that could be useful for future interventions.
Perceptions about why first-line drugs for uncomplicated
malaria change
It was not clear from the literature or from the study par-
ticipants how they got communication about earlier drug
changes from chloroquine to SP. However, the majority
of participants indicated that they learnt about new drugs
mainly through media advertisements and at health fa-
cilities. Given the profit motivation of drug companies
advertising through the media, most study participants
strongly believed that any change in treatment policy was
mainly driven by the desire for profit maximisation. This
view was shared by all FGD participants, 17 key informant
interviews, two district health managers, and four primary
health facility in-charges. A community leader said of the
changes:
“I think chloroquine is no longer available because the
company associated with it had made a lot of money
so the government thought it was time to give another
company chance to make money. That explains why
every time we have different types of drugs for
malaria.”
Other study participants believed that drugs change be-
cause the government keeps testing different drugs to es-
tablish the most effectiveness one against malaria. Asked
whether the change in malaria drugs was good for the
community, most participants in 12 FGDs and nine infor-
mal interviews reported that it did not contribute to better
treatment for malaria. They believed that any changes
were confusing, as stated by female FGD participant:
“The change of drugs is very bad because when we are
already used to one type of drug then one day we are
given a new one whose name we do not know. This
makes treatment difficult because we do not know
which drug to use anymore….”
However, six key informants out of 20 at the village level
understood the scientific basis for change of drugs and ex-
plained that drugs change due to treatment failure.
Awareness of the change from SP to AL
Nearly all study participants were aware of the existence
of AL but knew it only as “the drug with many tablets”.
They had no idea that it replaced SP as the official first-
line treatment for uncomplicated malaria. Only six people
(four women and two men) among all study participants
Okungu and Gilson Malaria Journal 2014, 13:258 Page 4 of 10
http://www.malariajournal.com/content/13/1/258
at the village level knew AL by name and recognized it as
the official first-line anti-malarial. These individuals had
formal jobs and better education than their peers had, and
were residents of a village near the urban section of the
study district.
There were mixed responses at the village level when
asked about the history of changes in first-line treatment.
Most respondents explained that drugs have changed
from CQ to amodiaquine (AQ) or from SP to a number of
painkillers as advertised through the radio. The respon-
dents further explained that the variety of drugs men-
tioned reflected people’s preferences since there was no
single drug that suited every malaria patient.
In the narratives, three malaria patients thought AL
was a painkiller and most men in the more remote vil-
lages believed that malaria drugs were seasonal and pre-
ferred CQ to AL. A 51 year old man said in an FGD:
“We do not know that drugs have changed, but we
know there are seasons for malaria drugs and it is
now the season for malaratab (amodiaquine) and that
other one with many tablets. When chloroquine season
returns, we will have no problems over which drug to
use to treat malaria…”
Perceived efficacy of AL compared with other drugs
Whenever people have negative attitudes toward a health
intervention, uptake is likely to be affected. A policy com-
munication strategy that accompanies change of health
interventions should pre-empt or change such nega-
tive attitudes. However, in the study area, a number
of respondents regarded AL as harmful. This was identi-
fied in 14 in-depth interviews, nine FGDs and seven infor-
mal interviews. Older individuals (50 years and above)
were particularly concerned that AL was more harm-
ful and less effective than CQ. One male key inform-
ant remarked:
“When taking the new drug (Coartem), we ask
ourselves many questions: ‘Where are they from and
why can’t we be given the ones that we know? What
harm can they cause to us?’ This makes us afraid…..
We use this drug but inwardly we ask ourselves why it
is different from the ones we used before and whether
they are any better in treating malaria….”
The perceived harm in AL was further emphasized in
the fact that it was not recommended for expectant
mothers. A young man said:
“Recently, I asked my wife why she was given fewer
drugs than those given to everyone who goes to the
dispensary and she told me that the other drug with
many tablets cannot be given to pregnant women.
That confirms the new drug can be harmful to anyone
else.”
Study participants classified malaria into two categories:
‘weak’ and ‘strong’. Weak malaria meant mild or non-
serious illness in which the patient is not incapacitated in
any way. Strong malaria on the hand meant that the
patient is perceived to be seriously ill with malaria and re-
quires urgent medical attention. A number of study par-
ticipants complained that one type of drug cannot be used
to treat both strong and weak malaria because using AL to
treat ‘weak’ malaria when it is a strong drug could render
it ineffective against ‘strong’ malaria and this could be
fatal. Those who perceived AL as weak cited its numerous
tablets (24 tablets for adult dose while SP had three tab-
lets). A female FGD participant said of AL tablets:
“We heard that malaria drugs that we are used to are
no longer good and hoped for a new and better drug,
but that is not the case because a full dose of the new
drug has 24 tablets instead of just a few. Why are the
tablets so many if it is a good drug?”
According to health workers, some of those who thought
that AL was weak were cases of recurrent malaria, which
sometimes led to the judgement that AL was weak. A
health worker confirmed that a few people who experi-
enced recurrent malaria after taking AL were reluctant to
use the drug again or seek any formal treatment at all.
Those seeking formal treatment were keen to use a differ-
ent health facility in the hope that they will not be given
the same drug (AL). Should they be given the same drug,
they were unlikely to take it, as confirmed by a female
FGD participant:
“If we suffer from malaria soon after taking all those
tablets, we demand for a different drug. That means
we would go to a different dispensary but if that
dispensary also issues the same drug, we bring those
drugs home to keep, then turn to herbs or go to private
clinics for injections....”
Barriers to health policy communication during the
change from SP to AL
A number of factors emerged as clearly influencing com-
munication around the change of first-line drugs for un-
complicated malaria.
Choice and preference of communication channels
The findings indicate that the choice of policy communi-
cation strategies used by the government during the
change to AL were not the most preferred in the study
area. Figure 1 summarizes how information about the
change from SP to AL was communicated to the public.
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These can be contrasted with Figure 2, which is a sum-
mary of the study community’s preferred communica-
tion channels for health policy communication.
Among the information, education and communica-
tion (IEC) tools used to facilitate the change from SP to
AL, only radio and posters seemed to have reached the
study district. However, the impact of these tools on the
primary caretakers, mostly women, was negligible be-
cause most radios were owned and controlled by men.
Although most people at health facilities were women
and potentially had access to posters advertising the
change to AL, widespread illiteracy made it impossible
for them to read the posters. A young woman said of
the posters:
“…all we see are graphics and pictures, which we think
are decorations on the dispensary walls.”
Study participants emphasized that they preferred
interpersonal communication to radios and posters and
the best sources would be public health officers (PHOs),
local authorities and teachers, and complemented by
radio communication. The interpersonal communication
allowed for exchange of views and prompt response to
Figure 1 Communication channels used by the government to pass information about the change of first-line treatment policy to AL.
Figure 2 The study community’s preferred channels of communicating policy changes in first-line treatment for uncomplicated malaria
and other health information in order of priority.
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community concerns about the newly introduced drugs.
For interpersonal communication however, the PHOs
were not part of the change process for lack of resources
to train them but a health manager acknowledged the
mistake in leaving out the PHOs:
“It was a mistake to leave out the PHOs because
their involvement would have ensured a more
successful implementation of the change
to AL.”
The health manager explained that emphasis on inter-
personal communication would have best clarified that
AL was the most suitable drug to treat malaria and
could also have eliminated confusion over which drugs
to use. A typical confusion over drugs was captured in
the following statement:
“…the dispensary gave my wife what it said were the
latest malaria drugs but the shopkeeper also had the
latest drugs different from the dispensary. This is
confusing.”
Provider-patient conflicts
Conflicts were manifest in three areas: provider-patient
communication, perceived health worker incompetence
and professional integrity. Study participants complained
of poor interpersonal relationships with health workers. In
the narratives, two patients complained about rude health
workers who refused to answer their queries about AL. A
mother said:
“I wanted to know why I was given malaria drugs
different from the ones I have known all along but the
nurse asked me whether I came to be treated or to ask
questions….”
Health workers admitted they rarely engaged pa-
tients about the change to AL because of the limited
time to attend to large numbers of patients. At least
one in-charge mentioned that it was not their respon-
sibility to discuss issues of adherence with patients
and saw no need to inform them about any changes
in treatment:
“The patients are usually very many and we cannot
engage each of them in lengthy conversations about
adherence. Besides, I have never considered it
important to engage the community on such issues as
change of drugs....”
The perceived inability of health workers to give proper
treatment affected use and adherence to AL. In six FGDs,
some study participants regarded presumptive treatment
as poor quality care and preferred diagnostic tests. A young
mother said:
“The health worker just looks at the baby and
prescribes treatment. How does he know what he is
suffering from without tests?”
Some health workers were also alleged to engage in
unethical practices including running private businesses
within public health facilities and allegations of sale of
facility drugs. A young man said:
“…the health worker shows you two types of drugs….
He would say, ‘This drug belongs to the government,
and these other one is mine. Mine is the best because
it is stronger; so you choose which one you want.’ His
drugs are indeed better but more expensive.”
Advertisements from private drug firms
A range of anti-malarials and other drugs sold over the
counter are often the subject of sustained marketing ad-
vertisement through the print and electronic media. The
continuous advertisement of such drugs by respective
companies overshadowed government advertisement of
AL the same media. Consequently, community members
could not differentiate between the drugs advertised by
the private companies and AL as the recommended
first-line drug. Concerns about the role of drug compan-
ies in limiting uptake of AL were expressed by health
workers:
“There is a lot of information coming through radios
and posters regarding different types of malaria drugs
and without anyone to differentiate for the ordinary
people and show them that Coartem is the best and
recommended drug… they get confused by the
adverts....”
In a few but important cases, the language used in the
advertisements by drug companies lacked clarity; for ex-
ample, among the study community and the wider Coastal
region, the term ‘homa’ can be translated to mean fever,
common cold and flu, but it also refers to febrile condi-
tions such as malaria. It was not always clear from the ad-
verts what type of ‘homa’ the advertised drugs treated and
so patients often used painkillers to treat malaria with the
understanding that they were drugs for ‘homa’. A health
worker commented:
“In this community, the word ‘homa’ means
different illnesses including common cold, stomach
upsets and malaria. Unless these are clarified in
the advertisement for drugs, the locals will continue
using painkillers in treating malaria....”
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Discussion
There was very limited knowledge within the study dis-
trict about what prompts changes in treatment policy.
Lack of such knowledge led to mostly negative interpre-
tations about why there had been changes in first-line
treatment for uncomplicated malaria. Specific to the
treatment policy change from SP to AL, the communica-
tion strategy employed to facilitate take up of AL had lit-
tle impact in the study district and instead seemed to
perpetuate negative perceptions about the change from
SP to AL. Although this study was conducted in 2009,
the issues it raises remain important for consideration in
future changes in treatment policies and accompanying
communication, particularly in remote settings.
One of the things that changing treatment policy and
the accompanying communication have to contend with
is the entrenched health seeking and treatment habits of
the target population. A number of authors such as
[14-16] have observed that treatment-seeking behaviour
is difficult to change once people get used to particular
drugs. Within the study district, use of familiar interven-
tions such as herbs, SP and AQ were widespread and
entrenched in people’s treatment culture. It was thus dif-
ficult for malaria patients to use AL as they demanded
to be given drugs familiar to them. Past studies in Kenya
by [7,15] noted that patients demanded for SP instead of
AL at health facilities, suggesting poor uptake of AL in
the initial stages.
To a large extent, our findings indicate that weak-
nesses in policy communication during the change from
SP to AL contributed to the poor uptake. Part of the rea-
son for the communication problems was that a number
of contextual factors relevant to the study population
were apparently not considered in the strategy applied.
Contextual factors, according to [2] influence health care
utilisation, service satisfaction, treatment adherence and
health outcomes at all levels. The context include health-
care process (information and its dissemination strategies,
health education campaigns and interpersonal engage-
ments) and ethno-social realities (linguistics, health be-
liefs, socioeconomic status and literacy) [2]. Our findings
highlighted similar contextual factors including resource
control within households, literacy and health beliefs
as well as information packaging and dissemination, and
interpersonal communication. Some studies such as [14,16,17]
have emphasized the critical role of contextual factors for
successful health policy communication. These factors de-
termine which policy communication tools or channels
would be most appropriate for a particular setting and
require exploration of the target population’s preferred
channels of health communication [16].
The government’s overreliance on the print (written)
and electronic media meant that communication about
the change to AL remained largely inaccessible to most
of the study population because of illiteracy and lack of
control of such resources as radio and the financial
means to maintain them. According to [2], poor com-
munities are least likely to benefit from written health
communication because of low levels of education and
literacy. In addition, and noting the importance in use of
language during health communication, [2] emphasize
that provision of health information should go beyond
the target group’s preferred language to ensure the infor-
mation provided matches literacy skills and delivered in a
culturally appropriate language. Appropriate use of lan-
guage could control non-adherence and use of ineffective
drugs, which are key catalysts in the development of drug
resistance with far-reaching implications for health sys-
tems. As noted by [18], practices that lead to development
of drug resistance are most common in poor rural areas
and so effective communication on drug changes is im-
perative in such areas to support correct use of drugs.
Recommendations by [2,19] also confirm that effective
health policy communication requires multiple channels
over a sustained period of time to be able to educate and
raise public awareness. Although the change from SP to
AL involved multiple channels, it did not include the
channel most preferred by the study population, i.e. inter-
personal communication involving the local authority,
teachers and health workers (particularly public health of-
ficers). An important aspect of health policy communica-
tion was therefore, not considered during the change from
SP to AL: that of engaging the community in the change
process. The role and active involvement of the commu-
nity in health interventions has been emphasized by
[5,20,21]. Importantly, delivery of health messages through
interpersonal means could have helped in passing consist-
ent information and limited divergent views about AL in
the study district. Views that AL was ‘weak’, ‘strong’ or
‘harmful’, that it was an experimental drug or from a com-
pany after profits, were contradictory and portrayed unin-
tended effects of a health intervention. According to [3],
unintended effects following a health intervention can be
due to differences in exposure to an intervention as well
as in interpretation of information. For the study district,
exposure to written and electronic means of communica-
tion promoted these unintended consequences because
they were largely inaccessible.
Central to interpersonal communication during health
policy communication is patient-provider engagement.
Community members understood health workers as ex-
perts in their field, which explained their strong prefer-
ence for public health officers as their preferred main
sources of health information. Health information com-
municated by experts, as perceived by the community, is
better received compared to communication from ordinary
persons [16]. Furthermore, communication between pa-
tients and health workers influences treatment outcomes
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and affects patients’ perceptions of provider competence
[22-24]. However, the fact that some patients in possession
of AL in the study district referred to it as a painkiller may
show the limited information received by patients from
providers about their diagnosis and treatment as well as
about the presence of new drugs for malaria. For better
health outcomes the need for clear, adequate and accurate
dialogue between culturally competent providers and pa-
tients has been emphasized [2].
Finally, negative perceptions about change of treatment
policy for uncomplicated malaria and about AL in particu-
lar, could also have emanated from lack of trust in overall
political governance given wider media and other reports
that described massive high level corruption, for example
[25]. Being an economically marginalized district, there
seemed to have been little confidence in public initiatives.
This may explain why an overwhelming majority of the
study participants including a few health workers saw the
change in first-line treatment policy from SP to AL as no
more than a commercial endeavour.
Conclusion
The study highlights the need for effective policy com-
munication using locally available channels during the
change of first-line treatment for uncomplicated malaria,
and perhaps for other drug regimen changes. In addition,
communication of the treatment policy change should be
supported by other actions such as training health workers
to open dialogue and effectively communicate with pa-
tients to inspire confidence in new drugs as well as a pro-
longed public education campaign that allows the public
to adjust to the newly introduced drug. Such an approach
should be able to increase the amount and quality of in-
formation received by beneficiaries, which is important for
take-up of new health interventions. Although this study
was undertaken only in one district, its detailed investiga-
tion of experience suggests that prompt access to effective
treatment may not be achieved in any other setting if
beneficiaries are not adequately prepared for changes in
drug regimens such as first-line treatment for uncompli-
cated malaria. The study suggests that future changes in
first-line drugs should ensure that treatment policy com-
munication is well designed to inspire trust and confi-
dence in the public, particularly among people in remote
settings, and to facilitate acceptance and take-up of
new health interventions. The choice of a communication
channel is as important as the intervention itself.
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